CUSA (Clarity Ultrasonic Surgical Aspirator) now has clearance for specific cardiac indications. Indications now encompass the debridement of unwanted tissue in cardiac surgeries. These include valve replacement and repair.
Princeton, New Jersey-based Integra said that, in addition to cardiac surgery, the FDA granted CUSA an indication for use in surgical procedures. These procedures include when fragmentation, emulsification and aspiration of soft and hard (bone) tissue is desirable. This extends CUSA’s uses to a range of surgeries beyond cardiac. Those include neurosurgery, plastic and reconstructive surgery, orthopedic surgery, thoracic surgery, laparoscopic surgery, gynecological surgery and liver resection and transplant surgery.
“The utilization of CUSA Clarity for cardiac surgery marks the next pivotal expansion of the ultrasonic surgical aspirator system’s breadth of indications,” said Mike McBreen, EVP and president of Integra’s Codman Specialty Surgical division. “As one of the leaders in the industry, this milestone strengthens our ability to deliver advanced surgical solutions to support restoring patients’ lives.”
CUSA Clarity’s console combines four components into one integrated system, according to the Integra LifeSciences website. The company designed it to provide the power and precision needed for quick, safe debulking of fibrous tissue. It pairs with multiple handpiece offerings.
The Power handpiece (23 kHz) offers use in more challenging neurosurgical procedures, such as tough tissue and bone removal. Integra’s Precision handpiece (36 kHz) offers more safety and control, according to the company.
